Risk marker profiles in patients treated with percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy

@article{Burghardt2018RiskMP,
  title={Risk marker profiles in patients treated with percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy},
  author={Amelie Burghardt and Frank van Buuren and Zisis Dimitriadis and Tim Gr{\"u}bbel and Hubert Seggewiss and Smita Scholtz and Dieter Horstkotte and Lothar Faber},
  journal={Clinical Research in Cardiology},
  year={2018},
  volume={107},
  pages={479-486}
}
Different studies have shown a good long-term survival with improvement of symptoms and hemodynamics after percutaneous septal ablation (PTSMA), similar to myectomy considered to be the therapeutic “gold standard” for symptomatic hypertrophic obstructive cardiomyopathy (HOCM). Furthermore, desobliteration of left ventricular (LV) outflow may modify features of the disease considered to be risk-relevant, such as magnitude of LV hypertrophy, outflow gradient, and left atrial (LA) size. The aim… CONTINUE READING
BETA

Citations

Publications citing this paper.

Genetic basis of hypertrophic cardiomyopathy in children

  • Clinical Research in Cardiology
  • 2018
VIEW 1 EXCERPT
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 36 REFERENCES

Prognostic impact of variables monitored during follow-up Statistically significant value is in bold Variable

SF Nagueh, SR Ommen, +7 authors WH Spencer
  • III and IV 52 IVS (mm) ≤
  • 2018

Similar Papers

Loading similar papers…